Technical Analysis for LPCN - Lipocine Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Spinning Top | Other | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Slingshot Bullish | Bullish Swing Setup | -2.39% | |
Calm After Storm | Range Contraction | -2.39% | |
Upper Bollinger Band Walk | Strength | -2.39% | |
Wide Bands | Range Expansion | -2.39% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 11 hours ago |
Down 3% | about 11 hours ago |
Down 2 % | about 11 hours ago |
Down 1% | about 11 hours ago |
Upper Bollinger Band Resistance | about 12 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/08/2024
Lipocine Inc. Description
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Alcohol Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Metabolism Bypass Ketones Testosterone Androstanes Preterm Birth
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.95 |
52 Week Low | 2.3101 |
Average Volume | 30,963 |
200-Day Moving Average | 3.66 |
50-Day Moving Average | 3.84 |
20-Day Moving Average | 3.96 |
10-Day Moving Average | 4.06 |
Average True Range | 0.36 |
RSI (14) | 65.28 |
ADX | 28.87 |
+DI | 30.91 |
-DI | 16.88 |
Chandelier Exit (Long, 3 ATRs) | 4.17 |
Chandelier Exit (Short, 3 ATRs) | 4.29 |
Upper Bollinger Bands | 4.69 |
Lower Bollinger Band | 3.22 |
Percent B (%b) | 0.86 |
BandWidth | 37.15 |
MACD Line | 0.18 |
MACD Signal Line | 0.09 |
MACD Histogram | 0.0911 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.02 | ||||
Resistance 3 (R3) | 5.05 | 4.90 | 4.93 | ||
Resistance 2 (R2) | 4.90 | 4.76 | 4.88 | 4.90 | |
Resistance 1 (R1) | 4.69 | 4.68 | 4.62 | 4.67 | 4.87 |
Pivot Point | 4.54 | 4.54 | 4.50 | 4.53 | 4.54 |
Support 1 (S1) | 4.34 | 4.41 | 4.26 | 4.31 | 4.11 |
Support 2 (S2) | 4.19 | 4.32 | 4.17 | 4.08 | |
Support 3 (S3) | 3.98 | 4.19 | 4.05 | ||
Support 4 (S4) | 3.96 |